2017-2018 年胸肿瘤学的科学进展：小细胞肺癌。
2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer.
机构信息
Oncology Department, Service of Immuno-Oncology, Lausanne University Hospital, Lausanne, Switzerland.
New York University Langone Health, New York, New York.
出版信息
J Thorac Oncol. 2019 May;14(5):768-783. doi: 10.1016/j.jtho.2019.01.022. Epub 2019 Feb 11.
SCLC remains an aggressive, deadly cancer with only modest effect on survival from standard chemotherapy. However, with the advent of immunotherapy and comprehensive genomic and transcriptomic profiling, multiple new targets are showing promise in the clinical arena, and just recently programmed death ligand 1 inhibition has been shown to improve the efficacy of standard chemotherapy in extended-disease SCLC. Our increasing understanding of the interactions between different pathways will enable more tailored immunotherapy and targeted therapies based on specific biomarkers and rational combinations. Here we discuss the preclinical and clinical strides in 2017 and 2018 that put us on the threshold of a new era in therapeutics and will, it is hoped, translate into significant improvements in survival.
小细胞肺癌仍然是一种侵袭性和致命性癌症，标准化疗对其生存仅有适度影响。然而，随着免疫疗法以及全面的基因组和转录组分析的出现，多个新靶点在临床领域显示出了希望，最近程序性死亡配体 1 抑制已被证明可提高广泛期小细胞肺癌的标准化疗疗效。我们对不同途径之间相互作用的认识不断加深，将使我们能够根据特定的生物标志物和合理的组合，为免疫治疗和靶向治疗制定更具针对性的方案。在此，我们讨论了 2017 年和 2018 年的临床前和临床进展，这些进展使我们迈入了治疗的新时代，并有望使生存得到显著改善。
Zotero 插件